The US Food and Drug Administration's approval of a mesenchymal stromal cell (MSC) therapy bodes well for Cynata Therapeutics (ASX:CYP), Euroz Hartleys said in a Dec. 19 note.
Cynata Therapeutics focuses on the development and commercialization of its platform technology, Cymerus, which enables scalable production of MSC-based products for human therapeutic use.
Last week, the regulator approved Ryoncil, Mesoblast's (ASX:MSB) MSC therapy for children aged 2 months and older, with steroid-refractory acute graft versus host disease.
Euroz Hartleys believes that the approval from the regulator signals openness to approving additional MSC-based therapies.
The investment firm maintained its speculative buy rating and price target of AU$0.67 on Cynata Therapeutics.
Shares of Cynanta Therapeutics rose 5% in recent Monday trade, and Mesoblast's shares surged almost 9%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。